India Pesticides Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0xpf2dk4k1xf2bqoaudc6wfc.pdf

Key Takeaways


Revenue Breakdown: Export Collapse, Domestic Resilience

Anand Agarwal: "One thing I can tell you that we can't give you as a particular at this moment, any concrete time frame, but our team, and we are quite hopeful that in coming 2-3 years, we are going to do wonders."

Margin Walk: The Inventory Hole and the Recovery Path

Dheeraj Jain: "Sir, what happens, if we want to take a 20% margin on a price for $60, it will be $12. So $12, they will say it is too much. The customers, the MNCs, when they calculate the cost of the raw material and the conversion costs and when they want the margin $12, they feel like we are charging too much, that's what they feel, in general. But in a low-value product like $5, then they don't question so much."

Capacity Build-Out: Sandila, Hamirpur and the Registration Subsidiary

Dheeraj Jain: "If we register once, initially it takes a little more time, but if you register once, then the business is assured. Because anyhow whenever we want to sell, we've got to increase our overall portfolio and revenues, then we need to register and increase our product portfolio."

Geographic and Portfolio Expansion


Succession and Governance

Dheeraj Jain: "This marks a momentous occasion for us, igniting the path towards an exciting leap into the future of exponential growth."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin recoveryRecover to 16–18% rangeNext 2 quarters
Newer-product EBITDAAchieve 20–22% EBITDA marginFrom next year onward
Gross margin target43–44% gross marginNext year
Residual inventory lossNo further material loss beyond 1–2%From here onward
Sandila capacity addition2,000 metric tonnes (1 intermediate block + 1 existing product capacity increase)By Q4 FY24
Hamirpur first block commissioningFirst molecule production startLast quarter of this financial year
International destockingDestocking to persistAnother 1–2 quarters
FY24 capex₹50 cr (IPL) + ₹60 cr (Shalvis Specialties), funded via internal accrualsFY24

Key Metrics

MetricQ2 FY24
Total revenue₹206 cr, vs ₹253 cr in Q2 FY23
EBITDA₹31 cr, sequential growth of 19%
EBITDA margin15%
Net profit₹20 cr
PAT margin9.5%
Export revenue₹62 cr, vs ₹122 cr in Q2 FY23
Domestic revenue₹140 cr, vs ₹128 cr in Q2 FY23
Technicals revenue₹115 cr
Formulation revenue₹87 cr
Inventory loss impact on EBITDA margin~500 bps decline in H1 FY24, from total ₹22 cr inventory loss on sales of ₹400 cr
Cash and cash equivalents₹168 cr at quarter end
Capex spent in H1 FY24₹30 cr
Capex planned for FY24 (IPL)₹50 cr
Capex planned for FY24 (Shalvis Specialties)₹60 cr
Total installed capacity26,000 metric tonnes per annum
Technicals and intermediates capacity addition planned2,000 metric tonnes, taking total to 23,200 metric tonnes, expected by Q4 FY24
Technical segment revenue share77% of total revenue
Domestic formulation distributors~5,000 across pan-India
Latin America share of Technical sales8% to 10%
EBITDA margin expectation for next year onwards20% to 22%
Gross margin target for next year43% to 44%